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Background: In Denmark 8,000 to 10,000 people will attempt suicide each year. The Centre of Excellence in Suicide
Prevention in the Capital Region of Denmark is treating patients with suicidal behavior, and a recent survey has
shown that 30% of the patients are suffering from borderline personality disorder. The majority of patients (70% to
75%) with borderline personality disorder have a history of deliberate self-harm and 10% have a lifetime risk to die
by suicide. The DiaS trial is comparing dialectical behavior therapy with collaborative assessment and management
of suicidality-informed supportive psychotherapy, for the risk of repetition of deliberate self-harm in patients with a
recent suicide attempt and personality traits within the spectrum of borderline personality disorder. Both treatments
have previously shown effects in this group of patients on suicide ideation and self-harm compared with treatment
as usual.
Methods/Design: The trial is designed as a single-center, two-armed, parallel-group observer-blinded randomized
clinical superiority trial. We will recruit 160 participants with a recent suicide attempt and at least two traits of the
borderline personality disorder from the Centre of Excellence in Suicide Prevention, Capital Region of Denmark.
Randomization will be performed though a centralized and computer-generated approach that conceals the
randomization sequence. The interventions that are offered are a modified version of a dialectical behavior therapy
program lasting 16 weeks versus collaborative assessment and management of suicidality-informed supportive psy-
chotherapy, where the duration treatment will vary in accordance with established methods up to 16 weeks. The
primary outcome measure is the ratio of deliberate self-harming acts including suicide attempts measured at week
28. Other exploratory outcomes are included such as severity of symptoms, suicide intention and ideation, depression,
hopelessness, self-esteem, impulsivity, anger, and duration of respective treatments.
Trial registration: Clinical Trial.gov: NCT01512602.
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In Denmark, the suicide rate is 11.9 per 100,000 people
per year according the World Health Organization [1].
Around 8,000 to 10,000 people attempt suicide each year
based on information registered in the National Patient
Register and the Register of Suicide. Patients who attempted
suicide have an increased risk of recurrent suicide attempts
and suicidal death [2]. Borderline Personality Disorder
(BPD), according to the DSM-IV [3], affects approximately
1% to 2% of the general population, and this patient group
represents up to 10% of all psychiatric outpatients and 20%
of all inpatients [2,4]. A total of 60% to 70% of the patients
with borderline personality disorder will attempt suicide,
and the lifetime risk of death by suicide is as much as 10%
[5], a risk 50 times higher than in the general population.
Approximately 70% to 75% of individuals with BPD, a con-
dition which is associated with challenges in regulating emo-
tions and difficulties in tolerating emotional distress [6],
exhibit nonsuicidal self-harm [6].
Dialectical behavior therapy is a manual-based treat-
ment, which was originally developed by the American
psychologist Marsha Linehan [6] for the treatment of
the core problems of patients with borderline personality
disorder, especially concerning emotional regulation, which
makes patients particularly prone to self-harming acts. The
treatment has shown positive effect in several randomized
trials to reduce the high risk of self-injury and suicide at-
tempt in patient with BPD compared with treatment as
usual [7-12]. A recent meta-analysis has shown DBT to be
the most evidence-based psychotherapeutic treatment for
borderline personality disorder and can reduce numbers of
self-harming acts and related secondary markers compared
with other psychotherapeutic treatments, for example, cog-
nitive behavioral therapy and interpersonal psychotherapy
[13]. DBT has also shown effect in treating other dysfunc-
tions such as drug dependence [14] and eating disturbances
[15]. A recent systematic review [16] describes seven differ-
ent studies where the DBT treatment duration varies from
3 to 12 months, and indicates that the most treatment gain
is made during the first 4 months of treatment.
The collaborative assessment and management of sui-
cidality (CAMS)-informed supportive psychotherapy was
developed by David Jobes and has been somewhat modi-
fied in conjunction with Danish colleagues for this study.
CAMS is considered both a philosophy of care and a
clinical therapeutical framework [17-19]. As a flexible
therapeutical framework, CAMS is trans-theoretical and
can thereby by used across theoretical orientations, clin-
ical techniques, and professional disciplines. CAMS is
designed to specifically target suicidal ideation and be-
havior as the central clinical focus, independent of diagno-
sis. Through collaborative assessment and deconstruction
of the patient’s suicidality, key problems and goals natur-
ally emerge. Collaborative treatment planning that followsthus creates a problem-focused approach that is designed
to reconstruct more viable ways of coping and living. Early
studies of CAMS have shown positive effects in reducing
suicide ideation in smaller studies with suicidal patients
on several parameters [19-23], but there is a need for fur-
ther research in well-powered clinical trials [24].
The two interventions - DBT versus CAMS - have
been chosen for the DiaS trial. They have not previously
been compared head to head. This trial will target pa-
tients with borderline personality traits and recent sui-
cide attempts.
Methods/Design
Our plan is to compare 16 weeks treatment of DBT versus
CAMS. The primary outcome will be the ratio of partici-
pants with suicide attempts or non-suicidal deliberate self-
harming acts (self-reported and registered in medical
records) during the treatment period in the treatment
period and at follow-up until week 28 after randomization.
This trial is designed as a single-center, two-armed,
parallel-group, observer-blinded randomized clinical su-
periority trial (Figure 1).
Recruitment and criteria for inclusion and exclusion
The patients are recruited through the Centre of Excel-
lence for Suicide Prevention, Capital Region of Denmark.
This is a highly specialized outpatient care center treating
450 patients annually and offering short-term supportive
psychotherapy and social counseling. The patients are re-
ferred from general practitioners and from somatic and
psychiatric wards after suicide attempts; patients can also
self-refer to the Centre. The patients will be referred to
the trial and screened by an assessor. If the patients fulfill
the inclusion criteria and none of the exclusion criteria
(see list of inclusion and exclusion criteria below), they be
will included in the trial and randomized by the first con-
tact therapist in the Centre of Excellence for Suicide Pre-
vention. In the screening interview patients will be
subjected to a Mini International Neuropsychiatric Inter-
view (MINI) [25] and a Structured Clinical Interview for
DSM-IV Axis II Personality Disorders [26]. Deliberate
Self-Harm (DSH) and recent suicide attempts will be mea-
sured by using Lifetime Suicide and Self-Injury (L-SASI)
[27] and Suicide Attempt and Self-injury Interview
(SASII) [28]. The therapist will contact the patients and
inform them of which group of the treatment they are to
be allocated. The adherence to the treatments in both
groups will be measured continuously. Follow-up inter-
views are performed in week 17, 28, and 52 after inclusion
Inclusion and exclusion criteria in the DiaS trial
Inclusion criteria
1) 18 to 65 years of age.
Patient recruitment
Patients are referred from the Centre of 




Baseline assessment and randomisation
DBT intervention CAMS informed supportive 
psychotherapy
28 weeks follow-up visit
52 weeks follow-up visit
17 weeks follow-up visit
Figure 1 The flowchart of the recruiting and randomization in the DiaS trial.
Andreasson et al. Trials 2014, 15:194 Page 3 of 8
http://www.trialsjournal.com/content/15/1/1942) Recent suicide attempt within one month from the
inclusion date.
3) At least two of the following criteria for borderline
personality disorder (DSM-IV)a:
a) Desperate efforts to avoid being betrayed or
abandoned in reality or in imagination.
b) A pattern of unstable and intense interpersonal
relationships characterized by a swinging between
extremes of idealization and devaluation.
c) Identity disturbance: markedly and persistently
unstable self-image or self-feeling.
d) Impulsivity in at least 2 areas that are potentially
self-harming (for example, sexual misconduct,
abuse, consumption, and overeating).
e) Repeated instances of suicidal behavior, gestures
or threats or self-harm.
f ) Affective instability.
g) Chronic feelings of emptiness.
h) Inappropriate intense anger or difficulty
controlling anger.
i) Transient, stress related paranoid ideation,
delusions or severe dissociative symptoms.
4) Informed consent.Exclusion criteria
– Severe depression.b
– Bipolar disorder.b
– Psychosis in schizophrenia spectrum.b
– Anorexia nervosa.b
– Alcohol or drug addiction.b
– Mental retardation.
– Dementia.
– Insufficient ability in speaking and understanding
Danish
– Lack of informed consent.
aAssessed by SCID-II [26].
bAssessed by Mini International Neuropsychiatric
Interview (MINI) [25].
All psychiatric departments in the Capital region of
Denmark have been informed of the DiaS trial through
meetings and leaflets (see inclusion criteria above). Pa-
tients with at least two traits from the BPD diagnosis
(DSM-IV) [3] and a recent suicide attempt are referred
through the Centre of Excellence in Suicide Prevention.
The suicide attempt has to be within a month from the
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to ensure the accuracy of reporting the intent and other
important circumstances (feelings, thoughts and behavior
prior to, at the time of, and after the suicide attempt). The
patients must speak and understand Danish sufficiently to
participate in the therapy sessions and the assessment of
the trial. The diagnostic criteria for exclusion have been
chosen to eliminate potential confounders in the trial and
ensure a homogenous group of patients.
Randomization and blinding
Patients will be randomized into one of two treatment
arms. The randomization is stratified by sex and previ-
ous number of self-harm acts (one versus multiple). This
is done to avoid the risk of patients with multiple self-
harm acts being overrepresented in one of the treatment
groups. The Copenhagen Trial Unit (CTU) will generate
a computer-generated random sequence randomization,
using alternating block sizes unknown to the investiga-
tors. The trial staff will contact the CTU for information
about allocation. The above-mentioned procedure en-
sures adequate allocation concealment. The patients and
therapists will not be blinded. We will use blinded out-
come assessors (see outcomes below).
Dialectical behavior therapy
Dialectical behavior therapy (DBT) consists of four com-
ponents: 1) individual therapy, 2) skills training in groups,
3) access to telephone contact with therapists, and 4)
supervision and consultations for the therapist to prevent
burn-out. The first aim of the therapy is organized around
a target hierarchy, which consists of 1) eliminating life-
threatening behavior including suicide attempts and delib-
erate self-harm, 2) eliminating treatment interfering be-
havior such as non-attendance and not doing homework,
and 3) ameliorating behaviors leading to a decreased qual-
ity of life (axis I disorders, social aspects, and drug de-
pendence). The second aim of the therapy is skill training
in groups. Patients are taught four modules of primary
skills: 1) mindfulness, 2) emotional regulation, 3) distress
tolerance, and 4) interpersonal effectiveness. The individual
therapy will focus on the taught skills in the groups. The
DBT treatment manual is based on DBT-A by Rathus and
Miller [29]. The DBT intervention will consist of 16 weeks
treatment defined as 2 hours weekly skill training in
groups, 1 hour weekly individual psychotherapy, op-
portunity of telephone coaching with the therapist,
and approximately 1 hour weekly team consultation
and supervision.
Collaborative assessment and management of
suicidality-informed supportive psychotherapy
The second intervention consists of supportive psycho-
therapeutic treatment within the framework of CAMS.CAMS-informed supportive psychotherapy is a psycho-
therapeutic approach based on principles from the ‘Col-
laborative assessment and management of suicidality’
[19]. The method typically employs a 45- to 60-minute
session once a week in the office of the therapist (in cri-
sis situations the length, frequency, and location of care
may vary). CAMS sessions have a specific structure
starting in the first 10 to 20 minutes with a collaborative
working through of the ‘core assessment’ of the ‘Suicide
Status Form’ (SSF), rating on a scale of 1 to 5 the follow-
ing six suicide-related markers: psychological pain, stress,
agitation, hopelessness, self-hate, and overall risk of sui-
cide. In the collaborative exploration of these and add-
itional SSF constructs, the patient and the therapist sit
side-by-side. Following the initial assessment, various
‘drivers’ of suicidality are identified and further investi-
gated. Direct drivers are thoughts, feelings, behaviors
and interpersonal themes that lead to suicidal thoughts
and acts. Indirect drivers are other factors that con-
tribute but do not directly lead to suicidal ideation or
feelings, such as: unemployment, depression, substance
abuse, post-traumatic stress disorder. A treatment plan
is collaboratively formulated that emphasizes a ‘crisis
response plan’ to establish outpatient stability. In
addition, the CAMS treatment plan further identifies, tar-
gets, and treats suicidal drivers with problem-focused inter-
ventions. On-going CAMS care involves the development
of coping skills for emergencies (for example, the elabor-
ation and use of a crisis response plan) as well as the
on-going linking of drivers and suicidality and problem-
focused interventions that treat those issues that makes
the patient suicidal. This philosophical and clinical ap-
proach to treatment is used in subsequent CAMS sessions
as the problem-focused treatment to ultimately eliminate
suicidal coping as much as possible.
The duration of the CAMS treatment differs depend-
ing on the patient’s suicidality. The therapist concludes
CAMS treatment after three successive contracts where
the patient is assessed to be non-suicidal according to
the SSF criteria [17]. In this study, the therapists are su-
pervised one and a half hours every second week.
Program fidelity
The trial staff consists of four clinical psychologists, two
nurses, a social worker, and an occupational therapist. All
have had courses and are trained in DBT and CAMS-
informed supportive psychotherapy. The training courses
offered the therapists were conducted by Alan Fruzzetti,
Professor at University of Reno, who trained the staff for
10 days in an intensive DBT training course that consisted
of four modules spread over a time period of 8 months
and by David Jobes, who held a 2-day course twice on
CAMS-informed supportive psychotherapy. The individ-
ual sessions with the patients will be videotaped and used
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group the rating scale to be used will be the DBT-global
rating scale by Marsha Linehan (unpublished work). The
therapist adherence to CAMS-informed supportive psy-
chotherapy will be assessed with the CAMS rating scale
(DA Jobes, unpublished work).
The CAMS intervention will be carried out at the
established departments of the Centre of Excellence for
Suicide Prevention, Capital Region of Denmark, Mental
Health Services, Psychiatric Centre of Copenhagen and
Psychiatric Centre of Amager. The DBT intervention will
be carried out at the Centre of Excellence for Suicide Pre-
vention, Psychiatric Centre of Copenhagen.
Assessments
The patients will be subjected to four almost identical
assessments. The first baseline assessment will be per-
formed in continuity with the assessment and validation
of the inclusion and exclusion criteria. Also the strata
used for the randomization will be obtained in the first
interview with the patient. The second assessment will
occur after treatment has ended in week 17 after inclu-
sion in the trial. The third and fourth assessment will




The primary outcome will be measured as the ratio of
deliberate self-harm before and after treatment (week 0
compared with week 28). The Suicide attempt and Self-
Injury Interview (SASII) [28] will be used to collect these
data and direct questions in the follow-up interview re-
garding self-harming behavior after inclusion in the trial.
We will also obtain information concerning numbers of
deliberate self-harm and suicide attempts through med-
ical records.
Explorative outcomes
In our trial we have chosen a number of exploratory out-
comes, which are not based on power calculations. These
include the severity of BPD symptoms, suicide intention and
ideation, depression, hopelessness, self-esteem, impulsivity,
and anger. We will also examine between-group differences
in ‘dosage’ and durations of the respective treatments.
Borderline personality disorder symptoms
The severity of features regarding borderline personality
symptoms is measured by the Zanarinis Rating Scale for
BPD. It is a nine-item, five-point scale (0 to 4, 0 = no
symptoms and 4 = severe symptoms) validated, clinician-
based diagnostic interview (DSM-IV) [30]. The categor-
ies of symptoms are affective, cognitive, impulsivity, and
interpersonal symptoms.Suicide intention and ideation
Suicide intention is measured by Beck’s Suicide Intent Scale
(SIS) [31,32]. It consists of 20 items, where the different cir-
cumstances and practical preparations are investigated.
The Beck Suicide Ideation Scale (BSS) is a 19-item
self-report questionnaire measuring suicidal thinking
[32]. Items are scored on a Likert scale ranging from 0
to 2, with a higher score indicating more severe suicidal
ideation.
Depression
Depressive symptoms will be assessed by Hamilton De-
pression Rating Scale (HDRS) 17-items [33]. The patients
are also subjects to Beck’s Depression Inventory (BDI)
[34,35], a 21-item self-report inventory of the depressive
symptomatology measuring depression. The BDI is the
most widely used research instruments and the items are
rated on a Likert scale from 0 to 3, where higher scores in-
dicate a more severe level of depressive symptoms.
Hopelessness, self-esteem, impulsivity, anger
The Becks Hopelessness Scale (BHS) consists of 20 true-
false items pertaining to future outlook [36]. Rosenberg’s
Self- Esteem scale (RSE) is used to assess the self-esteem.
It consists of 10 items and is a Likert scale with answers
using a four-point scale -from strongly agree to strongly
disagree [37].
Barratts Impulsivity Scale 11 (BIS-11) is a 30-item
questionnaire measuring impulsive personality traits
[38]. It yields a total score, three second-order factors,
and six first-order factors [39]. To measure anger, we
will use State Trait Anger Scale (STAS), developed by
Charles Spielberger [40]. It consists of 20 items in a self-
report questionnaire and is rated on a Likert scale with
answers using a four-point scale -from never to always.
Sample size and statistical analyses
Based on previous estimations, we expect the risk of
renewed self-harming acts within their first year to be 50
percent in the CAMS treatment group [6]. We expect
the DBT to be able to reduce this risk to 25 percent, a
relative risk reduction of 50%. With a power of 90% and
a type one error probability associated with this test of
0.05, we plan to randomize 154 patients, with about 77
patients in each intervention group. We will handle
missing data using logistic regression with multiple im-
putations as described below.
The two group baseline characteristics will be com-
pared using Student’s t-test for independent samples or
a chi-square test for binary variables.
The primary analysis will be based on the intention-
to-treat principle; that is, data from all patients will be
included in the treatment group to which they were allo-
cated regardless of degree of compliance.
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sion and continuous outcomes will be analyzed using
linear regression with baseline variables as sex and previ-
ous deliberate self-harm as a covariates.
If more than 5% of the primary outcome is missing at
follow-up, we will use multiple imputations (SPSS version
19.0). If this is the case, the multiple imputations will be
considered the primary result. For multiple imputations,
we will use a linear regression model with 100 imputations
and 20 iterations. The pooled estimates from the imputa-
tions will subsequently be used for our analysis.
We will use two-tailed tests for statistical significance
with alpha set at P <0.05.
Ethical considerations
The trial protocol is approved by the regional ethics com-
mittee in the Capital Region of Denmark under file num-
ber H-1-2011-042. The Danish Data Protection Agency
has approved the management of data in the trial under
the file number 2007-58-0015. Finally, the trial is regis-
tered under ClinicalTrial.gov as NCT01512602. In accord-
ance with the CONSORT guidelines [41], we will publish
negative, neutral and positive findings in the trial.
We have decided not to have a control group without
any intervention, because of the ethical aspects when
treating suicidal and vulnerable patients.
The patients will be informed about the trial with both
verbally and with written information before signing the
written consent. It will be stressed that participation in
the trial is voluntary. Participation and the written con-
sent can be withdrawn at any time in the trial, and this
can be done with no consequence for future treatment
possibilities.
Discussion
The DiaS trial is designed as a pragmatic trial, with the
intention of intervening in the exiting clinical outpatient
setting, so one could argue the patient population is se-
lected beforehand. The Excellence Centre for Suicide
Prevention has their exclusion criteria before offering
treatment as mentioned before and can exclude patients
for whom treatment can appear too demanding. The
chosen target group includes patients with emotional
dysregulation leading to suicide attempts. This patient
group is over-represented in the Centre of Excellence in
Suicide Prevention. The chosen experimental DBT treat-
ment is based on a modified DBT manual but where all
the skills taught are maintained. The DBT treatment
period of 16 weeks is shorter than in the majority of
other randomized clinical trials performed [16]. The
considerations of these modulations are the excepted oc-
currence of the lesser chronicity and severity in BPD
symptoms in the target group of patients. The patients
only have to fulfill two out of nine BPD criteria accordingto the DSM-IV. Regarding the CAMS-informed supportive
psychotherapy given to the control group, this treatment
has been an obvious choice as the majority of therapist in
the Excellence Centre for Suicide Prevention use this treat-
ment. This treatment group can be considered as an
optimized ‘treatment-as-usual’ control group, where the
therapists are trained and supervised, and treatment ad-
herence is rated.
The two different intervention groups will receive dif-
ferent amounts of time of individual psychotherapy, and
the CAMS group is not offered skill training in groups.
We consider the different amounts of time in the two
groups as inevitable because of the different basic con-
struction of the two psychotherapeutic treatments. In
the CAMS- intervention group the therapist has to fin-
ish the treatment when achieving three consecutive non-
suicidal scores on the SSF. A strength of this trial is the
centralized randomization [42], which reduces the risk
of selection bias. We will perform blinded outcome
assessment to reduce bias [43]. We will use intention-
to-treat analysis and multiple imputations to reduce the
bias introduced by missing data in our analysis [43].
A related post-hoc consideration is the potential ‘cost-
effectiveness’ of the respective treatments in relation to
frequencies of hospitalizations, emergency department
visits, and primary care visits. The cost-effectiveness of
clinical care for high-risk patients was previously exam-
ined in a retrospective study of CAMS versus treatment-
as-usual with suicidal outpatients [44] and is a topic of in-
creasing importance within contemporary mental health
care around the world.
The DiaS trial is a single center trial and can therefore
be considered as a pilot trial for multicenter trials in the
future. In order to obtain external validity, we need mul-
ticenter trials. The DiaS trial has a 52-week follow-up
period to investigate deliberate self-harm and suicide at-
tempts after treatment. This knowledge can be useful in
the design of trials, in regard to treatment duration or to
booster treatment sessions. Moreover we need trials
showing comparable effects both during the interven-
tion period and the post-intervention period.
Trial status
The status of the trial is recruitment of patients, which
began in January 2012 and is expected to finish in January
2014. We must recruit 154 participants, and we find this
goal realistic because it is estimated that approximately
30% of the patients in the target group at the Excellence
Centre for Suicidal Prevention will fulfill the inclusion cri-
teria for the DiaS trial.
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